Neurocrine Biosciences, Inc. (NBIX)

Neurocrine Biosciences Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	2,355	1,887	1,489	1,134	1,046
Revenue Growth (YoY)	24.81%	26.76%	31.34%	8.38%	32.71%
Cost of Revenue	765.1	604.7	487	342.4	285.1
Gross Profit	1,590	1,282	1,002	791.1	760.8
Selling, General & Admin	1,007	887.6	752.7	583.3	433.3
Operating Expenses	1,007	887.6	752.7	583.3	433.3
Operating Income	583	394.8	249	207.8	327.5
Interest Expense	-	-	-	-25.8	-32.8
Interest & Investment Income	91	52.8	4.1	3.8	12.6
EBT Excluding Unusual Items	674	447.6	253.1	185.8	307.3
Gain (Loss) on Sale of Investments	-37.1	28.4	30.8	20.9	-17.7
Other Unusual Items	-138.4	-	-70	-	-18.4
Pretax Income	486	332.1	213.9	101.4	106.7
Income Tax Expense	144.7	82.4	59.4	11.8	-300.6
Net Income	341.3	249.7	154.5	89.6	407.3
Net Income to Common	341.3	249.7	154.5	89.6	407.3
Net Income Growth	36.68%	61.62%	72.43%	-78.00%	1000.81%
Shares Outstanding (Basic)	100	98	96	95	93
Shares Outstanding (Diluted)	104	101	99	98	98
Shares Change (YoY)	2.67%	2.12%	1.02%	0.10%	2.19%
EPS (Basic)	3.40	2.56	1.61	0.95	4.37
EPS (Diluted)	3.29	2.47	1.56	0.92	4.16
EPS Growth	33.20%	58.33%	69.56%	-77.89%	966.67%
Free Cash Flow	557.2	361.6	322.9	233.1	217.6
Free Cash Flow Per Share	5.37	3.58	3.27	2.38	2.23
Gross Margin	67.52%	67.96%	67.29%	69.79%	72.74%
Operating Margin	24.75%	20.92%	16.73%	18.33%	31.31%
Profit Margin	14.49%	13.23%	10.38%	7.90%	38.94%
Free Cash Flow Margin	23.66%	19.16%	21.69%	20.57%	20.80%
EBITDA	610.1	416.1	264.6	218.7	336.1
EBITDA Margin	25.90%	22.05%	17.77%	19.29%	32.14%
D&A For EBITDA	27.1	21.3	15.6	10.9	8.6
EBIT	583	394.8	249	207.8	327.5
EBIT Margin	24.75%	20.92%	16.73%	18.33%	31.31%
Effective Tax Rate	29.77%	24.81%	27.77%	11.64%	-
Revenue as Reported	2,355	1,887	1,489	1,134	1,046
Advertising Expenses	191	159.9	149.7	139.8	64.8

Updated Feb 10, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q